Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.0002730897METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS
RU 26.08.2020
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2020121770 Applicant Inventor Костин Никита Николаевич (RU)
FIELD: medicine. SUBSTANCE: invention refers to medicine and molecular biology. Essence of the invention is that for the purpose of detecting antibodies belonging to different classes of immunoglobulins, in blood serum or plasma of patients with COVID-19 or infected with said virus, uses a complex of antigenic recombinant proteins (RBD-SD1 and NTD fragments of spike-protein of SARS-CoV-2 virus, as well as nucleoprotein of SARS-CoV-2 virus, obtained on the basis of artificially synthesized genetic structures in plasmid DHFRControlTemplate, incorporated into strain BL21 (DE3) E.coli. Target recombinant proteins are sorbed in the pits of the folding polystyrene microplates, based on which the test system is formed, including four sets of reagents for both total and separate determination of IgM-, IgG-, IgA-antibodies to SARS-CoV-2 in laboratory diagnostics and clinical-epidemiological monitoring of COVID-19. Invention can be used for producing test systems for serological diagnosis of COVID-19 in order to assess the humoral immune response in infected individuals and epidemiological characteristics of the infectious process in the population, and in the future – to determine the effectiveness of vaccination and immunotherapy when obtaining and implementing the corresponding therapeutic and preventive preparations against SARS-CoV-2. EFFECT: invention provides complete and comprehensive assessment of the immune response to SARS-CoV-2. 10 cl, 5 dwg, 1 tbl, 3 annexes
2.111569057新型冠状病毒肺炎DNA疫苗及其制备方法和应用
CN 25.08.2020
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010454745.0 Applicant 吉林省中科生物工程股份有限公司 Inventor 梁磊
本发明公开了一种新型冠状病毒肺炎DNA疫苗及其制备方法和应用,该DNA疫苗将传统新型冠状病毒RBD序列N‑1位的糖基化天冬酰胺删除,可以增加表达水平,并保持其功能性和抗原性。RBD△N可引发高滴度的针对假病毒和活病毒的中和抗体。同时,编码蛋白是以pVAX1为载体骨架分子,并对基因启始密码子ATG的前后碱基序列作了设计和调整,使其符合Kozak规则,该DNA疫苗重组体转染293细胞,RT‑PCR及Western Blot检测表明,目的蛋白成功表达,表达产物可以被标准血清所识别。
3.111575242一种用于COVID-19药物筛选的iPSC-nCoVN细胞模型及其建立和使用方法
CN 25.08.2020
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No 202010500970.3 Applicant 广东源心再生医学有限公司 Inventor 林彬
本发明公开了一种用于COVID‑19药物筛选的iPSC‑nCoVN细胞模型及其建立方法和使用方法,属于生物医药技术领域。该细胞模型是通过nCoVN的cDNA来构建pCW‑nCoVN的载体,然后对HEK293T细胞进行慢病毒包装后转染iPSC细胞获得。本发明首次建立了可用于COVID‑19药物筛选的细胞模型,其检测方法简便、操作难度低、检测速度快、可通量操作,并且可以在无病毒的安全环境中快速评价受试药物是否能够抑制nCoVN蛋白的作用,减少或消除其对iPSC增殖速率和多能性的影响,从而达到药物筛选目的,无安全风险;用于抗COVID‑19候选药物的筛选,为COVID‑19的治疗提供科学依据。
4.111560354重组新型冠状病毒及其制备方法和应用
CN 21.08.2020
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No 202010439738.3 Applicant 中国人民解放军总医院第五医学中心 Inventor 杨鹏辉
本发明公开了重组新型冠状病毒及其制备方法和应用。本发明首先公开了重组病毒,该重组病毒的流感病毒的NS基因、流感病毒的HA基因和流感病毒的NA基因中任一种基因被替换。本发明进一步公开了上述重组病毒在制备预防和/或治疗流感病毒和/或SARS‑CoV‑2引起的疾病的产品中的应用。本发明从基因水平对SARS‑CoV‑2抗原表位和流感病毒基因组进行操作,基于RG技术制备流感病毒为载体的重组SARS‑CoV‑2疫苗株,解决了SARS‑CoV‑2疫苗短缺难题,将是冠状病毒疫苗领域的新里程碑,且SARS‑CoV‑2嵌合疫苗可以保护更多人群免受流感病毒和SARS‑CoV‑2之害。
5.111544583CS/HPMCP纳米微粒在口服疫苗递送中的应用
CN 18.08.2020
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010413064.X Applicant 西北农林科技大学 Inventor 肖书奇
本发明公开了CS/HPMCP纳米微粒在口服疫苗递送中的应用,属于动物病毒学和动物基因工程技术领域。为了检测CS/HPMCP纳米微粒口服递送的免疫效力,本发明选取猪流行性腹泻病毒作为试验对象;本发明通过大肠杆菌表达系统表达COE蛋白,进一步通过离子交联方法制备了载有COE的CS/HPMCP纳米颗粒,并且评估了给小鼠口服载有COE的CS/HPMCP纳米微粒后,小鼠的体液免疫、细胞免疫和粘膜免疫;旨在为研发口服型纳米微粒佐剂提供有力的技术支持,同时为PEDV口服型亚单位疫苗的研究奠定前期基础。
6.111529701一种口服后产生新型冠状病毒抗体的制剂及其制备方法
CN 14.08.2020
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010408158.8 Applicant 内蒙古自治区国际蒙医医院(内蒙古自治区蒙医药研究所) Inventor 杨德志
本发明公开了一种口服后产生新型冠状病毒抗体的制剂及其制备方法。本发明以减毒沙门氏菌为载体传送DNA疫苗,通过口服肠溶胶囊有效到达肠道低毒感染送DNA疫苗到肠道内皮细胞,通过巨噬细胞吞噬细菌,表达特异性分子COVID‑19‑S,被免疫细胞识别,从而在哺乳动物(老鼠、人等哺乳动物体内)达到产生特异性的抗体中和COVID‑19‑S蛋白从而达到,免疫的效果。
7.111537721SARS-COV-2 Spike蛋白在新冠肺炎检测中的应用
CN 14.08.2020
Int.Class G01N 33/58
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
58involving labelled substances
Appl.No 202010300582.0 Applicant 杭州泰熙生物技术有限公司 Inventor 周斌
本发明公开了SARS‑COV‑2 Spike蛋白在新冠肺炎检测中的应用。本发明获得稳定、高表达SARS‑COV‑2 Spike蛋白S1蛋白亚基重组蛋白的HEK293细胞株,并将SARS‑COV‑2 Spike蛋白S1蛋白亚基重组蛋白应用于免疫层析检测试剂的研制。本发明使用SARS‑COV‑2 Spike蛋白S1蛋白亚基重组抗原作为标记材料,并应用于金标免疫层析系统,该检测体系为直接标记捕获,与以原核表达的SARS‑COV‑2 NP重组蛋白为包被的IgM/IgG检测产品相比较,灵敏度和特异性均较大幅度的提高。
8.WO/2020/161107NOVEL FISH CORONAVIRUS
WO 13.08.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/EP2020/052688 Applicant PHARMAQ AS Inventor NYLUND, Stian
The invention relates to a novel fish virus, indicated to be a Coronavirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.
9.3693465NOVEL FISH CORONAVIRUS
EP 12.08.2020
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 19155627 Applicant PHARMAQ AS Inventor NYLUND STIAN
The invention relates to a novel fish virus, indicated to be a Coronavirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.
10.111518175SARS-COV-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
CN 11.08.2020
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010392553.1 Applicant 广州派真生物技术有限公司 Inventor 周泽鑫
本发明公开了SARS‑COV‑2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用,所述的抗原多肽序列如SEQ.ID.NO.1和SEQ.ID.NO.2所示。所述的重组腺相关病毒是将将pHelper、pRep2Cap5和抗原多肽的表达载体共孵育,在转染试剂聚乙烯亚胺存在的条件下转染细胞,培育细胞后,经过裂解和纯化,得到含有重组腺相关病毒的纯化液。本发明的重组腺相关病毒在体内递送表达产生融合抗原多肽,诱导产生血清中和抗体,对SARS‑COV‑2新冠病毒具有中和效价,并持续表达,可用于对人进行针对COVID‑19新冠肺炎的免疫接种。